Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Realcan Pharmaceutical Group Co's FCF Margin % or its related term are showing as below:
SZSE:002589'
s FCF Margin % Range Over the Past 10 Years
Min: -13.29 Med: -0.51 Max: 3.29
Current: -0.56
During the past 13 years, the highest FCF Margin % of Realcan Pharmaceutical Group Co was 3.29%. The lowest was -13.29%. And the median was -0.51%.
SZSE:002589's FCF Margin % is ranked worse than 63.25% of 117
companies
in the Medical Distribution industry
Industry Median: 0.47
vs SZSE:002589: -0.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co FCF Margin % Chart
SZSE:002589 vs MCK, COR, CAH: FCF Margin % Comparison
For the Medical Distribution subindustry, Realcan Pharmaceutical Group Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Realcan Pharmaceutical Group Co FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Realcan Pharmaceutical Group Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Realcan Pharmaceutical Group Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Realcan Pharmaceutical Group Co (SZSE:002589) has a FCF Margin % of -0.52% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Realcan Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Realcan Pharmaceutical Group Co ranks #74 out of 117 companies in the Medical Distribution industry, placing it in the top 63.2%.
Is Realcan Pharmaceutical Group Co's FCF Margin % too high?
Realcan Pharmaceutical Group Co's current FCF Margin % is -0.52%. Based on the distribution chart, Realcan Pharmaceutical Group Co ranks #74 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Realcan Pharmaceutical Group Co has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Realcan Pharmaceutical Group Co's FCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Realcan Pharmaceutical Group Co ranks #74 out of 117 companies for FCF Margin %. This places Realcan Pharmaceutical Group Co in the lower half of its industry. The industry median FCF Margin % is 0.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 0.47, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Realcan Pharmaceutical Group Co and its competitors. For the Medical Distribution industry, the median FCF Margin % is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Realcan Pharmaceutical Group Co's current FCF Margin % is -0.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Realcan Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co (SZSE:002589) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.35, compared to a current price of ¥3.53 — trading 50.2% above its estimated fair value. The current FCF Margin % is -0.52%. Realcan Pharmaceutical Group Co's overall GF Score™ is 50/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Realcan Pharmaceutical Group Co (SZSE:002589), the current FCF Margin % is -0.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Realcan Pharmaceutical Group Co (SZSE:002589) Overvalued in 2026?
Based on GuruFocus' analysis, Realcan Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥3.53 is trading 50.2% above its estimated GF Value™ of ¥2.35.
GuruFocus considers Realcan Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SZSE:002589:
FCF Margin %: -0.52%
GF Value™: ¥2.35 vs. price of ¥3.53 (50.2% above fair value)
No single metric tells the full story. See the SZSE:002589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
50GF Score
Get the complete analysis for SZSE:002589
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002589 has been successfully added to your 
